On February 11, 2026, Suning, director of the Hematology Department of the Sixth Affiliated Hospital of Sun Yat-sen University, and Shi Guojun, researcher and doctoral supervisor of the Endocrinology Department of the Third Affiliated Hospital of Sun Yat-sen University, visited Shenzhen-Hong Kong Cell Valley to carry out special research and cooperation negotiations in the field of cell therapy. They focused on the two core directions of cell therapy and product development of new cell therapies for hematological tumors and refractory obesity, and accurately responded to the development requirements of the State Council Order No. 818 "Regulations on the Management of Clinical Research and Clinical Transformation Application of New Biomedical Technologies". Cell Valley Group Chairman Howard Shi, Chief Scientist Wang Jianxun and other relevant persons in charge warmly received the reception. The two parties conducted in-depth exchanges on technology research and development, clinical transformation, compliance implementation and other aspects.

At the symposium, Director Suning introduced in detail the profound clinical accumulation and scientific research achievements of the Hematology Department of the Sixth Affiliated Hospital of Sun Yat-sen University in the field of hematoma diagnosis and treatment, focusing on the current pain points of clinical treatment of refractory and recurrent hematomas, as well as the current application status and improvement space of cell therapy technology in the field of hematomas. Professor Shi Guojun shared the diagnosis, treatment and clinical needs of refractory obesity. He introduced the research characteristics of the Endocrinology Department of the Third Affiliated Hospital of Sun Yat-sen University in the field of metabolic diseases, analyzed the physiological characteristics of people with refractory obesity, the limitations of traditional treatment methods, and the cutting-edge research directions of cell therapy in the field of metabolism.

Chairman of Cell Valley Howard Shi highly recognized the professional sharing of the two experts. He pointed out that hematoma is a mature application field of cell therapy technology, and as refractory obesity is an important type of metabolic disease, the development of new cell therapy products has become a cutting-edge research hotspot in the industry. Both are innovative application directions of cell therapy technology.

This research and negotiation laid a solid foundation for Cell Valley to establish an in-depth industry-university-research cooperation mechanism with the corresponding departments of the Sixth Affiliated Hospital of Sun Yat-sen University and the Third Affiliated Hospital of Sun Yat-sen University. In the next step, Cell Valley will focus on the core directions of cell therapy for hematomas and refractory obesity, accelerate the planning and implementation of specific cooperation projects, strictly follow the regulatory requirements for clinical research and transformation of new biomedical technologies, jointly carry out scientific research and product development, and jointly create innovative results of cell therapy technology in the field of tumors and metabolic diseases.

微信公众号

市场部：赖女士